These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 27161449

  • 1. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
    Mochel MC, Ming ME, Imadojemu S, Gangadhar TC, Schuchter LM, Elenitsas R, Payne AS, Chu EY.
    J Cutan Pathol; 2016 Sep; 43(9):787-91. PubMed ID: 27161449
    [Abstract] [Full Text] [Related]

  • 2. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
    Parakh S, Nguyen R, Opie JM, Andrews MC.
    Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
    [Abstract] [Full Text] [Related]

  • 3. Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.
    Perret RE, Josselin N, Knol AC, Khammari A, Cassecuel J, Peuvrel L, Dreno B, Supported by GESTIM Nantes group of cutaneous adverse events induced by anticancer drugs.
    Int J Dermatol; 2017 May; 56(5):527-533. PubMed ID: 28188628
    [Abstract] [Full Text] [Related]

  • 4. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.
    Rofe O, Bar-Sela G, Keidar Z, Sezin T, Sadik CD, Bergman R.
    Clin Exp Dermatol; 2017 Apr; 42(3):309-312. PubMed ID: 28211077
    [Abstract] [Full Text] [Related]

  • 5. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K, McGettigan S, Elenitsas R, Chu EY.
    J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
    [Abstract] [Full Text] [Related]

  • 6. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions.
    Jour G, Glitza IC, Ellis RM, Torres-Cabala CA, Tetzlaff MT, Li JY, Nagarajan P, Huen A, Aung PP, Ivan D, Drucker CR, Prieto VG, Rapini RP, Patel A, Curry JL.
    J Cutan Pathol; 2016 Aug; 43(8):688-96. PubMed ID: 27086658
    [Abstract] [Full Text] [Related]

  • 7. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.
    Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, Postow MA, Weinstein A, Lucas AS, Ciccolini KT, Quigley EA, Lesokhin AM, Paik PK, Chaft JE, Segal NH, D'Angelo SP, Dickson MA, Wolchok JD, Lacouture ME.
    Cancer Immunol Res; 2016 May; 4(5):383-9. PubMed ID: 26928461
    [Abstract] [Full Text] [Related]

  • 8. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
    Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, Carlino MS, Kefford R, Fernandez-Penas P.
    J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
    [Abstract] [Full Text] [Related]

  • 9. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.
    Carlos G, Anforth R, Chou S, Clements A, Fernandez-Peñas P.
    Melanoma Res; 2015 Jun; 25(3):265-8. PubMed ID: 25831416
    [Abstract] [Full Text] [Related]

  • 10. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
    Tetzlaff MT, Nagarajan P, Chon S, Huen A, Diab A, Omar P, Aung PP, Torres-Cabala CA, Mays SR, Prieto VG, Curry JL.
    Am J Dermatopathol; 2017 Feb; 39(2):121-129. PubMed ID: 28134729
    [Abstract] [Full Text] [Related]

  • 11. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions.
    Chen WS, Tetzlaff MT, Diwan H, Jahan-Tigh R, Diab A, Nelson K, Glitza IC, Kaunitz GJ, Johnson D, Torres-Cabala C, Pacha O, Taube JM, Maloney K, Prieto VG, Curry JL.
    J Cutan Pathol; 2018 Oct; 45(10):764-773. PubMed ID: 29943453
    [Abstract] [Full Text] [Related]

  • 12. Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
    Hwang SJE, Fernández-Peñas P.
    Curr Probl Dermatol; 2018 Oct; 53():82-92. PubMed ID: 29131040
    [Abstract] [Full Text] [Related]

  • 13. Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: A case series.
    Morris LM, Lewis HA, Cornelius LA, Chen DY, Rosman IS.
    J Cutan Pathol; 2020 Aug; 47(8):742-746. PubMed ID: 32196722
    [Abstract] [Full Text] [Related]

  • 14. Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma.
    Amber KT, Valdebran M, Lu Y, De Feraudy S, Linden KG.
    J Dtsch Dermatol Ges; 2018 Feb; 16(2):196-198. PubMed ID: 29389067
    [No Abstract] [Full Text] [Related]

  • 15. Erythema multiforme major in a patient with metastatic melanoma treated with nivolumab.
    Sundaresan S, Nguyen KT, Nelson KC, Ivan D, Patel AB.
    Dermatol Online J; 2017 Sep 15; 23(9):. PubMed ID: 29469720
    [Abstract] [Full Text] [Related]

  • 16. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
    Blakeway EA, Elshimy N, Muinonen-Martin A, Marples M, Mathew B, Mitra A.
    Melanoma Res; 2019 Jun 15; 29(3):338-341. PubMed ID: 30762712
    [Abstract] [Full Text] [Related]

  • 17. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies.
    Hwang SJ, Carlos G, Chou S, Wakade D, Carlino MS, Fernandez-Penas P.
    Melanoma Res; 2016 Aug 15; 26(4):413-6. PubMed ID: 27031539
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
    Kawsar A, Edwards C, Patel P, Heywood RM, Gupta A, Mann J, Harland C, Heelan K, Larkin J, Lorigan P, Harwood CA, Matin RN, Fearfield L.
    Br J Dermatol; 2022 Dec 15; 187(6):981-987. PubMed ID: 35976170
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.